What insurance policy changes affect HCPCS J3387?

There are 17 tracked policy changes affecting HCPCS J3387, including updates from Anthem BCBS, Blue Cross Blue Shield of North Dakota, Humana. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for HCPCS J3387?

Payers that have issued tracked updates for HCPCS J3387 include: Anthem BCBS, Blue Cross Blue Shield of North Dakota, Humana.

How do I get notified when HCPCS J3387 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to HCPCS J3387. You will receive a daily digest email whenever a new policy change references this code.

Why do payers change policies for HCPCS J3387?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

J3387 — Injection, elivaldogene autotemcel, per treatment: Insurance Policy Changes

J3387 Insurance Policy Changes

HCPCS J3387 is officially defined as "Injection, elivaldogene autotemcel, per treatment." HCPCS J3387 is referenced in 17 tracked payer policy changes from Anthem BCBS, Blue Cross Blue Shield of North Dakota, and 1 other payer. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS J3387 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Medium impact

[Ohio] Precertification/prior authorization list change notification

Anthem BCBS·Effective Dec 1, 2026

Anthem Blue Cross and Blue Shield (Ohio) is adding 14 new services to its precertification/prior authorization requirements effective December 1, 2026. These additions include four specialized laboratory tests (Alzheimer's biomarkers, IBS serology, infectious disease sequencing, prostate cancer protein biomarkers), two irreversible electroporation procedures, six carotid sinus baroreceptor stimulation device codes, and two gene therapy treatments. All affected services will require prior authorization before billing to avoid claim denials.

J3387 Insurance Policy Changes

[Ohio] Precertification/prior authorization requirement changes

[California] Precertification/prior authorization requirement changes

[Virginia] Prior authorization requirement changes

[Virginia] Precertification/prior authorization requirement changes

[Georgia] Precertification/prior authorization list change notification

[California] Prior authorization requirement changes

[California] Prior authorization requirement changes

[New York] Prior authorization requirement changes

[New York] Precertification/prior authorization requirement changes

[Ohio] Precertification/prior authorization requirement changes

[Virginia] Prior authorization requirement changes

[Georgia] Precertification/prior authorization requirement changes

[New York] Precertification/prior authorization list change notification

[Virginia] Precertification/prior authorization list change notification

[Ohio] Precertification/prior authorization list change notification

Pharmacy Policy Updates

Skysona (elivaldogene autotemcel) - Medicare Advantage (Revised)